EMEA-001258-PIP01-11-M08
Submitted by Anonymous (not verified) on 19 September 2024 - 13:11
EMEA-001258-PIP01-11-M08
Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023
Submitted by Anonymous (not verified) on 19 September 2024 - 13:10
Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023
Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0395/2022
Submitted by Anonymous (not verified) on 19 September 2024 - 13:08
Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0395/2022
Antimicrobial Sales and Use (ASU) Platform: Release notes
Submitted by Anonymous (not verified) on 19 September 2024 - 12:40
Antimicrobial Sales and Use (ASU) Platform: Release notes
EMEA-002326-PIP04-20-M01
Submitted by Anonymous (not verified) on 19 September 2024 - 11:50
EMEA-002326-PIP04-20-M01
Opinion/decision on a Paediatric investigation plan (PIP): Kaftrio, elexacaftor,tezacaftor,ivacaftor, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0392/2023
Submitted by Anonymous (not verified) on 19 September 2024 - 11:49
Opinion/decision on a Paediatric investigation plan (PIP): Kaftrio, elexacaftor,tezacaftor,ivacaftor, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0392/2023
EMEA-002310-PIP01-17-M01
Submitted by Anonymous (not verified) on 19 September 2024 - 11:49
EMEA-002310-PIP01-17-M01
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0353/2023
Submitted by Anonymous (not verified) on 19 September 2024 - 11:48
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0353/2023
Opinion/decision on a Paediatric investigation plan (PIP): Tavneos, Avacopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0352/2023
Submitted by Anonymous (not verified) on 19 September 2024 - 11:47
Opinion/decision on a Paediatric investigation plan (PIP): Tavneos, Avacopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0352/2023
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0379/2023
Submitted by Anonymous (not verified) on 19 September 2024 - 11:46
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: P/0379/2023